Education
About Us
Working with TipRanks
Follow Us
Elite Pharmaceuticals (ELTP)
OTHER OTC:ELTP
Total Valuation
Elite Pharmaceuticals has a market cap or net worth of $653.39M. The enterprise value is $464.34M.
Market Cap$653.39M
Enterprise Value$464.34M
Share Statistics
Elite Pharmaceuticals has 1,070,963,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,070,963,100
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Elite Pharmaceuticals’s return on equity (ROE) is -0.08 and return on invested capital (ROIC) is 1809.64%.
Return on Equity (ROE)-0.08
Return on Assets (ROA)-0.04
Return on Invested Capital (ROIC)1809.64%
Return on Capital Employed (ROCE)0.23
Revenue Per Employee1.31M
Profits Per Employee-67.42K
Employee Count64
Asset Turnover0.87
Inventory Turnover2.71
Valuation Ratios
The current PE Ratio of Elite Pharmaceuticals is ―. Elite Pharmaceuticals’s PEG ratio is 0.90.
PE Ratio―
PS Ratio5.53
PB Ratio8.68
Price to Fair Value8.68
Price to FCF94.25
Price to Operating Cash Flow38.06
PEG Ratio0.90
Income Statement
In the last 12 months, Elite Pharmaceuticals had revenue of 84.04M and earned -4.31M in profits. Earnings per share was 0.00.
Revenue84.04M
Gross Profit40.09M
Operating Income19.60M
Pretax Income-52.14K
Net Income-4.31M
EBITDA2.84M
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was 22.73M and capital expenditures -1.08M, giving a free cash flow of 21.66M billion.
Operating Cash Flow22.73M
Free Cash Flow21.66M
Free Cash Flow per Share0.02
Dividends & Yields
Elite Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.55
52-Week Price Change3.03%
50-Day Moving Average0.64
200-Day Moving Average0.55
Relative Strength Index (RSI)66.53
Average Volume (3m)951.20K
Important Dates
Elite Pharmaceuticals upcoming earnings date is Feb 16, 2026, TBA (Confirmed).
Last Earnings DateNov 14, 2025
Next Earnings DateFeb 16, 2026
Ex-Dividend Date―
Financial Position
Elite Pharmaceuticals as a current ratio of 4.88, with Debt / Equity ratio of 14.00%
Current Ratio4.88
Quick Ratio3.50
Debt to Market Cap0.02
Net Debt to EBITDA-0.14
Interest Coverage Ratio25.38
Taxes
In the past 12 months, Elite Pharmaceuticals has paid 4.26M in taxes.
Income Tax4.26M
Effective Tax Rate-81.75
Enterprise Valuation
Elite Pharmaceuticals EV to EBITDA ratio is 163.34, with an EV/FCF ratio of 94.17.
EV to Sales5.52
EV to EBITDA163.34
EV to Free Cash Flow94.17
EV to Operating Cash Flow62.28
Balance Sheet
Elite Pharmaceuticals has $26.62M in cash and marketable securities with $3.32M in debt, giving a net cash position of $23.30M billion.
Cash & Marketable Securities$26.62M
Total Debt$3.32M
Net Cash$23.30M
Net Cash Per Share$0.02
Tangible Book Value Per Share$0.04
Margins
Gross margin is 55.80%, with operating margin of 23.32%, and net profit margin of -5.13%.
Gross Margin55.80%
Operating Margin23.32%
Pretax Margin-0.06%
Net Profit Margin-5.13%
EBITDA Margin3.38%
EBIT Margin0.86%
Analyst Forecast
The average price target for Elite Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target―
Price Target Upside―
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast58.70%
EPS Growth Forecast-152.33%